Early and severe CNS involvement occurs in some lysosomal storage disorders such as Tay-Sachs disease, 1 type II Gaucher disease 2 and the infantile form of Krabbe disease. 3 In these diseases, lysosomal storage and considerable neuropathology was observed even prior to birth. [1] [2] [3] [4] The deterioration of the CNS progresses rapidly soon after birth and causes the early death of the patient. To date, there is no specific or effective treatment to alter the neuropathology in the CNS after birth even when treatment was initiated in the neonatal period. In utero treatment may be needed to delay the onset and progression of the neuropathology and prevent the formation of irreversible damage in the CNS before birth. Although in utero bone marrow transplantation has been challenged clinically, 5 shortage in donor supply and graft-versushost disease limit the clinical application of this treatment. Prenatal gene therapy to the CNS may be a potential candidate in avoiding these constraints.
Studies on prenatal gene transfer showed that gene transduction was achieved in many organs such as the lung, [6] [7] [8] the digestive tract, 7 the liver [9] [10] [11] [12] and the heart 9, 10 via various routes such as intra-amniotic, [6] [7] [8] intraplacental, 9 into yolk sac vessels 10 and directly to the embryo. 11, 12 Recombinant adenovirus was the most often used vector because of its advantages in prenatal gene transfer, such as having a broad host range, the relative easiness in obtaining high titers and its powerfulness in gene transduction and expression. Reports on the transduction of therapeutic genes using recombinant adenovirus in utero showed reversal of phenotypes in murine models of cystic fibrosis 13 and hemophilia A. 14 However, there is no report as yet about prenatal gene transfer to the CNS parenchyma. Our aim in this study is to investigate its feasibility.
Between embryonic day 9 and 12 (E9-E12), recombinant adenovirus (AxCALacZ) encoding the E. coli ␤-galactosidase (␤-gal) gene driven by the CAG (cytomegalovirus enhancer-chicken ␤-actin promoter) promoter 15 was administered to rat embryos (6 × 10 6 p.f.u. per embryo). The reason why these embryonic stages were chosen is that we expected the viral vector to be able to infect CNS when the neural tube is not completely closed (before E11). 16 In order to define the site of injection, Evans Blue (2%) was injected to embryos by introducing a 30-gauge needle into the ventral third of the decidual swelling where the embryo resided. 17 The immediate analysis revealed that in most cases dye was injected into the amniotic cavities (data not shown). Recombinant adenoviruses were injected to individual embryos according to the method described above. The PBS-injected embryos of the same litter were taken as controls. Three days after injection, embryos were harvested. Gene transduction patterns were studied histochemically using X-gal staining.
Efficient gene transfer to the CNS was achieved when AxCALacZ was injected at E12. The distribution of the transgene in the brain is summarized in Table 1 . When analyzed 3 days after injection, strong LacZ expression in the CNS was mainly observed at two regions: one is the telencephalon surrounding the potential olfactory bulb; the other is the hypophysis and part of the hypothalamus near the hypophysis. Totally, nine out of 26 surviving To determine the duration of the transgene expression in the CNS, the E12-injected embryos were analyzed 1 week after injection and 1 week after birth (16 days after injection). The embryos examined 1 week after injection exhibited essentially the similar transgene expression pattern as that analyzed 3 days after injection, although with some decrement in the intensity and number of ␤-gal-positive cells. ␤-Gal-positive cells were also seen in the olfactory bulb (2/6), the hypophysis and surrounding connecting tissues (3/6), olfactory epithelium (3/6), olfactory nerve fibers (1/6) and the skin (4/6) (Figure 1g-i) . In the brain of the pups that received AxCALacZ injection at E12, some ␤-gal positive cells scattering in the olfactory bulb (2/5) and the hypophysis (1/5) were still detectable 1 week after birth (not shown). Unexpectedly, no detectable ␤-gal-positive cell was observed in the CNS in the embryos injected at E9-E11, as it had been speculated that gene transfer to the CNS may be obtained in these early development stages. When analyzed 3 days after each injection time by X-Gal staining, the ␤-gal-positive organs in E9-injected embryos (survival rate 61%, n = 36) were the primordia of the liver, esophagus and stomach (15/22) (Figure 2a and b) . Whereas, in E10-injected embryos (survival rate 43%, n = 35) the main positive organ was the heart (7/15) ( Figure  2c and d) . When adenoviruses were injected at E11 (survival rate 62%, n = 21), almost all of the surviving embryos exhibited strong blue staining in the skin (12/13) (Figure 2e ). No other organ showed detectable LacZ expression, including the brain. When analysis was performed 1 week after injection, the expression pattern is similar to that described above, although the intensity of blue staining decreased (data not shown).
This study demonstrates that efficient gene transfer to the CNS of rat embryos could be achieved by intra-amniotic administration of adenoviruses at E12, the gene transferred regions mainly localized at the olfactory bulb and hypophysis and the transgene expression in these regions persisted at least 1 week after birth. No transgene expression was observed in the CNS in the embryos that received the viral injection at E9-E11, but observed mainly in the liver, heart and skin, respectively. Although some variations in the intensity of blue staining had been observed among individual embryos, the expression patterns at the same injection time are similar and reproducible. The results could not be considered to be due to the technical aspects of the injection procedure.
The successful gene transfer to the telencephalic regions surrounding the olfactory bulb in the embryos which received injection at E12, most possibly occurred by retrograde axonal transport of the injected virions, through the termini of the olfactory nerve fibers. Developmentally, olfactory nerves just reach the antero-inferior wall of the telencephalon at E12. This may provide the access of virions presenting in amniotic fluid to the brain regions by first infecting the olfactory epithelium then being transported through the axons of olfactory nerves. This speculation is partly supported by the olfactory epithelium and olfactory nerve fibers towards the olfactory bulb which were observed to be ␤-gal-positive (Figure 1f and i). Similar retrograde gene transfer to the CNS by nasal instillation of adenovirus in adult animal has been reported previously. 18 We also speculate that gene transduction to the hypophysis is through the pharynx since the adenohypophysis is originally developed from a part of pharynx and the duct connecting the adenohypophysis and pharynx are still open at E12 (see ␤-gal-positive pharynx and the duct connecting adenohypophysis and pharynx at Figure 1d ). Our study showed that the transgene expressed in brain parenchyma, which is different from the observations described by Baldwin et al 19 in their study. They showed that transgene predominantly expressed in endothelial cells. This may mainly be due to the different tissue-specific activities of promoters used. They used the cytomegalovirus (CMV) enhancer/promoter, whereas a hybrid promoter (CAG promoter) was used in our study, which is generated by connecting the CMV enhancer to the modified chicken ␤-actin promoter. 15 Generally CAG promoter is stronger than CMV promoter and more ubiquitous. Indeed, Baldwin et al observed complete different expression pattern by using Rous sarcoma virus (RSV) long terminal repeat (LTR) promoter.
In the embryos that received AxCALacZ injection at E9 and E10, the transgene-expressing organs clearly differed depending on the timing of injection. Similar phenomena have been reported previously. 9, 10 This may due to different adenoviral internalization depending on the dynamic regulation of integrin ␣ v ␤ 3 /␤ 5 9,20 and/or different levels of tissue-specific promoter activities 19 during development.
The expression of the transgene in the CNS was attenuated rapidly when being analyzed over a period of time after injection. It may result from the immunoreactions to the proteins produced from adenoviral genome or the
Figure 1 Transgene expression in E12 injected embryos 3 days (a-f) and 1 week (g-i) after injection. Male and female Wistar rats were mated and the day a vaginal plug was found was counted as E0. Recombinant adenovirus carrying E. coli ␤-galactosidase gene (AxCALacZ) was the generous gift of Dr I Saito (University of Tokyo)
. 27 Adenovirus was purified and titered as previously described. 28 The final titer of adenovirus was 6 × 10 8 p.f.u./ml. non-integrative property of adenovirus. There is no significant inflammatory reaction observed in the brain, liver or other organs histologically. Previous studies also indicated that little immune response occurs in fetal rodents 8, 10 compared with other species such as sheep and rabbit, in which significant inflammatory response was observed. 21, 22 Thus the non-integrative property of adenovirus vector tends to play an important role in the decrement of transgene expression. Semi-quantitative PCR using specific primers for the LacZ gene revealed reduced copy number of the LacZ gene over time in the recipient brain (data not shown). The possible causes could be: (1) degradation of adenovirus DNA in the infected neuroblasts; (2) dilution of adenovirus DNA in the infected neural stem cells during further divisions; (3) relative dilution caused by the rapid increasing number of uninfected cells in the developing brain. The transient expression feature of the adenovirus limits itself to achieve persistent therapeutic effects by a single prenatal injection. Our study demonstrated the feasibility of gene delivery into the developing brain prenatally, but from the therapeutic point of view for genetic diseases that require long-term correction of the defective gene, the integrative or life-long virus vectors such as adeno-associated virus (AAV) vector 23 are more desirable rather than adenovirus. Retrovirus is integrative but the low transduction efficiency resulting from low titer and requiring divisions of cells for infection is a disadvantage. In this way adeno/retroviral chimeric vector 24, 25 should be considered useful for obtaining both efficient transduction and persistent gene expression. Prenatal diagnosis of many genetic disorders can be achieved by amniocentesis or chorionic villus sampling (CVS). This makes fetal therapy possible at early gestational stages. CVS could be performed as early as 9 weeks gestation, 26 and intra-amniotic administration is possible thereafter. The intra-amniotic route is acceptable since it has relatively low risk by avoiding directly introducing trauma to the fetus itself. However, the usefulness of this approach should be evaluated first in the rodent or primate models of genetic diseases. An experiment using a viral vector expressing ␤-galactocerebrosidase, the deficient enzyme in human Krabbe disease, in attempting prenatal treatment in the Twitcher mouse (the murine model of Krabbe disease) is underway.
Ten microliters of AxCALacZ was injected into individual embryos by introducing a 30-gauge needle with a Hamilton syringe directly through the uterus wall into the ventral third of the decidual swelling 17 at E12. Three days after injection, the embryos were harvested and whole embryos were fixed in 2% paraformaldehyde and 0.25% glutaraldehyde in PBS at 4°C for 1-2 h, washed well with PBS, and incubated in X-

